Cgix 201506

Investor Presentation
June 2015
Cancer Genetics, Inc.
Nasdaq
(CGIX)

Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 2
This presentation contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development and potential opportunities for Cancer Genetics,
Inc. products and services, along with other statements about the future expectations, beliefs, goals,
plans, or prospects expressed by management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to, statements that contain words such as "will,"
"believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties, including, without limitation,
risks inherent in the development and/or commercialization of potential products, risks of cancellation of
customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be
realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain
future capital, maintenance of intellectual property rights and other risks discussed in the Company's
Forms 10-K for the year ended December 31, 2014 and 10-Q for the quarter ended March 31, 2015
along with other filings with the Securities and Exchange Commission. These forward-looking statements
speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-
looking statements.
Forward-Looking Statement

Fact Sheet
Market Cap $95.07 Mn
Stock Price $9.13 [5/11/2015]
Ticker Symbol Nasdaq: CGIX
Qtrly Revenue (yoy) 117.6%
Total Cash $28.6 Mn
Facilities
• Rutherford, NJ
• Raleigh, NC
• Hyderabad, India
• Shanghai, China
18,000 sq. ft.
28,000 sq. ft.
14,000 sq. ft.
3,000 sq. ft.
Clients
• Cancer Centers
• Physician Offices
• Research Orgs.
• Hospitals
• Biotech
• Biopharma
Products 8 Launched Products
Patents 8 US Issued Patents
Cancer Genetics, Inc.
*Financial data as of 5/12/2015

Recent Highlights
2014-2015
 Agreement with Three Rivers
Provider Network expanded
 FHACT® partnership with
PathAdvantage
 Partnership with AstraZeneca to
provide biomarker & MDx testing
 Biopharma contracts increased to
$30 Mn+
 NYS licensure for FHACT®
 Agreement with America’s Choice
Provider Network®
 Focus::CLL™ selected for use in
global clinical trial by leading
biotech company
 Acquisition of
Gentris
Corporation
 Acquisition of
BioServe India
 Collaborative kidney cancer
study with Cleveland Clinic
results announced
 Collaborations with Keck
Medicine of USC & Beth Israel
Deaconess Medical Center for
diffuse large B-cell lymphoma
 Next Gen Sequencing
Collaboration with Columbia
University for myelodysplastic
syndromes & acute myeloid
leukemia
 Multi-Year Collaboration with
Moffitt Cancer Center for
genomics-based prediction of
chemotherapy side effects
Acquisitions
Research
Collaborations
Business
Growth
 Awarded
additional
kidney cancer
patent for
UroGenRA®-
Kidney
 Awarded two
cervical cancer
patents for
FHACT®
 Launch of MatBA®-FL &
MatBA®-MCL for follicular
lymphoma & mantle cell
lymphoma
 Launch of CALR mutation
test for acute leukemias &
myeloproliferative
neoplasms
 Upgraded MatBA®-CLL/SLL
algorithm for patient
stratification; add’l CLIA &
NYS Licensure
 Launch of Focus::CLL™,
Focus::Myeloid™, &
Focus::Hotspot™ NGS
panels
Product
Launches Patents

Genomic Testing has Paved the Way for Significant
Advancements in Diagnosis & Targeted Treatment Options
Comprehensive
Report
Proprietary
Products
Focused
Oncology Lab
OUR INTEGRATED APPROACH TO MOLECULAR
TESTING BRINGS BENEFITS ACROSS THE ENTIRE
ONCOLOGY ECOSYSTEM
DIAGNOSIS
Do I have cancer and if so,
what type?
PROGNOSIS
What course will my
cancer take? What should I
expect?
THERANOSIS
What are my treatment
options? Which drug is the
best fit for me?

Business Overview
8 Genomic Tests Launched
Research & Development Biotech/Biopharma
3,622
5,946
6,871
11,912
2011 2012 2013 2014
Clinical Test Volume (2011-2014)
17 Current Research Collaborations
Clinical Laboratory
NGS Panel Development:
Contracts with 6 of the top 10 pharma companies
Hematologic
Cancers:
Urogenital
Cancers:
Cervical
Cancer:
35% CAGR

We are Positioned to be the Oncology Diagnostics
Partner of Choice in Attractive Markets
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics
U.S.
China
India
$6 Bn
$1 Bn
N/A
Clinical
$2.5 Bn
$0.4 Bn
$1 Bn
Biopharma

Major Drivers for our Proprietary Programs
Is there an unmet patient need?
Is it unique & can it drive an IP-ready position?
Can we leverage the existing routine sample?
Can we validate and collaborate with major
research centers?
Can it be offered as part of our Complete™
programs?
1
2
3
4
5

Eight US Patents Awarded
7 Proprietary Diagnostic Products Addressing 1.2 Mn
Cases Globally Launched & in Market
Hematologic Cancers Cases per Year (global) CGI Test
Chronic Lymphocytic Leukemia 106,770 Focus::CLL™, MatBA®-CLL/SLL
Diffuse Large B-Cell Lymphoma 142,360 MatBA®-DLBCL
Follicular Lymphoma 62,300 MatBA®-FL
Mantle Cell Lymphoma 17,795 MatBA®-MCL
Urogenital Cancers Cases per Year (global) CGI Test
Kidney Cancer 340,000 UroGenRA®-Kidney
Cervical Cancer Cases per Year (global) CGI Test
Cervical Cancer 528,000 FHACT®

Significant Progress in Targeted NGS Panel Pipeline
* OncospireGenomics: a joint venture with Mayo Clinic
RESEARCH & DISCOVERY CLINICAL DEVELOPMENT COMMERCIAL DEVELOPMENT LAUNCH & MARKET ENTRY
FOCUS::CLL™
FOCUS::MYELOID™ (INCOLLABORATION WITHILLUMINA)
FOCUS::LYMPHOID™
MULTIPLE MYELOMA (VIAONCOSPIRE*)
FOLLICULAR LYMPHOMA (VIA ONCOSPIRE*)
HEMATOLOGIC CANCERS
FOCUS::RENAL™
UROGENITAL CANCERS
FOCUS::HOTSPOT™ (INITIAL LAUNCHIN INDIA)
LUNG CANCER (VIAONCOSPIRE*)
SOLID TUMOR
COMPREHENSIVE PHARMACOGENOMICS PANEL
PHARMACOGENOMICS (PGX)
TEST IN MARKET
TEST IN MARKET
TEST IN MARKET

11Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics
OncoSpire Genomics
Developed by Cancer Genetics, Inc. and Mayo Clinic
 World class NGS facility
 Best in class bioinformatics
 Immediately integrated into care
 Disease focus and stewardship
 Commercial focus and mgmt
 Capital access and investment
SELECTED PROJECTS HAVE THE
POTENTIAL TO BECOME CLINICAL
STANDARD OF CARE IN NGS-BASED
ONCOLOGY MANAGEMENT
 Only Joint Venture by the Mayo Clinic in
the Oncology space
 Core operations leverage Mayo facilities
in Rochester, MN
 $1M funded in 2013 to initiate JV, $2M
in 2014, up to $3M additional based on
milestones
 Projects with 12 to 30 month
development horizon; Multiple Myeloma
panel to launch in 2015
200,000
new cases
20,920
new cases
1.6 million
new cases
Informed
Discovery
Clinical
Development
Commercial
Development
Market Entry
(with partners)
Multiple Myeloma
Follicular Lymphoma
Lung Cancer

Multiple Myeloma:
Setting the New Standard with a Focused NGS Panel
A comprehensive NGS-based
panel will be developed to…
To target a major unmet need growing globally:
Identifying MGUSs that need follow-up & Tx and
determining best treatments for malignancies
Provide Greater Certainty & Reduce Complexity of
Diagnosis Replaces cyto, FISH & gene expression profiling1.
2. Earlier, More Accurate, Cost-Effective Prediction of MM
Identify mutations that predict change from MGUS to MM
• 88 genes selected for panel
• DNA sequencing complete for first
60 samples
• Analysis underway comparing 3
different analytical methods to
determine best solution
• In process of optimizing clinical
laboratory design from extraction to
reporting solution
• 3 papers in the publication process
• 2 international early-access
collaborations established

Focus::CLL™ NGS Panel
 Launched in Q4 2014
 Unique targeted NGS panel with 7 biomarkers for diagnosis, prognosis and patient
management
 The only targeted NGS panel available for CLL/SLL
 Selected for use in global clinical trial by a leading biotechnology company
 18,200 new cases per year
 150,000 people living with the disease
Numbers Behind the Disease
 Chronic Lymphocytic Leukemia (CLL)
 Small Lymphocytic Lymphoma (SLL)
Clinical Indications
(United States)
http://www.cancergenetics.com/laboratory-services/specialty-tests/focus-ngs/focuscll/

Focus::Myeloid™ NGS Panel
 Launched in Q1 2015
 Comprehensive NGS panel with 54 biomarkers that provides actionable information
for improved diagnosis, prognosis, and risk stratification
 Delivers faster results on biomarkers in current diagnostic and treatment guidelines
 Expands therapy options for patients with appropriate enrollment in clinical trials
 Selected for use in multiple clinical trials
 54,000 new cases per year
 274,000 people living with the disease
Numbers Behind the Disease
 Acute myeloid leukemia (AML)
 Myelodysplastic syndrome (MDS)
 Myeloproliferative neoplasms (MPN)
Clinical Indications
(United States)
http://www.cancergenetics.com/laboratory-services/specialty-tests/focus-ngs/focusmyeloid/

MatBA®-CLL/SLL Drives Improved Management of Patients
with Chronic Lymphocytic Leukemia (CLL)
Favorable/
Intermediate
(no distinction)
Unfavorable
85%
15%
FISH
4 Genomic Aberrations
Risk stratification by FISH, classifies
patients into only two groups:
 Favorable/Intermediate
(no distinction)
 Unfavorable
38% of cases are
favorable falling
under "watch &
wait" approach.
8% of unfavorable
cases missed by
FISH are caught by
MatBA®-CLL/SLL.23%
39%
38%
20 Genomic Aberrations
Favorable
Intermediate
Unfavorable
MatBA®-CLL/SLL is both CLIA & NYS licensed
to stratify patients into three distinct risk groups:
 Favorable
 Intermediate
 Unfavorable

[Kanti Rai, Nicholas Chiorazzi,
Jacqueline Barrientos]
Significance of Current Prognostic Markers in CLL in
the B-Cell Receptor Signaling Pathway Inhibitor Era
Zydelig™ [Idelalisib (PI3K-delta)]
 FDA Approved For CLL in the relapse setting
when considering Rituximab alone
 Collaborative project in progress at CGI
 Insights will be integrated into our
CLL Complete™
IMBRUVICA™ [Ibrutinib (BTK)]
 FDA Approved for CLL with 17p loss and in the
relapse setting where two prior therapies have failed
 Genomic alterations associated with resistance
 Acquired Mutations during therapy in BTK
Gene (C481S), PLCG2 (R665W)
 Deletion of 8p
 Gain of 3q
B-CELL RECEPTOR SIGNALING
PATHWAY INHIBITORS

Solution
UroGenRA®-Kidney Can Guide Management of Patients
with Renal Masses and Appropriate Treatment Selection
Development of diagnostic algorithm
 >600 RCC malignant subtypes (in-silico: SNP)
 >100 malignant and benign renal neoplasms (in-house: aCGH & FISH)
Retrospective in-house FFPE validation (n>190) CCF
diagnostic yield
diagnostic sensitivity to distinguish benign from malignant renal neoplasms
sensitivity to distinguish malignant RCC subtypes
Prospective ongoing percutaneous core needle biopsy (n>50) MSKCC
 Demonstrated ability to diagnose pathologically “unclassifiable” biopsies prior to
surgical intervention
Men and women with renal masses often
undergo unnecessary nephrectomy for accurate
diagnosis and experience delay in treatment
Problem
UroGenRA® will detect genomic aberrations in a single assay
permitting accurate diagnosis (benign vs malignant, and malignant
subtype) guiding appropriate management and treatment strategies
[C. Magi-Galluzzi and E. Klein]
[J. Coleman and J. Durack]

FHACT® Fits Directly into Today’s Cervical Cancer
Screening Workflow
Today, all these women are
referred for colposcopy.
Not referred
for colposcopy
Referred for
colposcopy
PROGRESS to a higher grade and
increased risk for cancer within 10-30
years of the infection.
REGRESS within 2 years of
the infection.
FHACT®
Results:
Normal
FHACT®
Results:
Abnormal
 Today, all HPV+ women with abnormal
Pap results are referred for colposcopy
 Several cervical cancer tests are
available but the need for less invasive
and better informed treatment exists
 FHACT® helps triage before colposcopy
 No resampling
 Fewer women referred for colposcopy
 Reduced healthcare costs

FISH-based HPV-Associated Cancer Test
FHACT® assesses non-random genomic alterations associated with
progression of lesion.
 Gain of 3q26 (TERC) has been detected with increasing frequency in
cervical lesions with increasing severity and is observed in about 75% of
cervical cancers.
[1-2]
 Gains of 5p15, 20q13 & chr 7 share a similar pattern of appearance in
precancerous cytology specimens by FISH (40-45%, 20q13, and 15%
respectively).
[3-4]
 Performed on remnant liquid based cytology.
 Gain at any of the FHACT® loci is detected in up to 89.5% of all
cervical cancers.
[5]
FHACT® presents the highest sensitivity on the market (4 loci).
1. Heselmeyer-Haddad K, et al. (2005). Am. J. Pathol. , 166, 1229-1238
2. Seppo A., et al. (2009) Gynecol Oncol, 114, 80-83
3. Scotto, L., et al. (2008). Mol Cancer, 7, 58.
4. Luhn P, et al. (2013). Gynecol Oncol, 130, 595-600.
5. The Cancer Genome Atlas (TCGA) (http:/cancergenome.nih.gov)
FHACT® Can Aid in Identifying Women with Markers of
High Grade Lesions (Cervical Cancer)
FHACT® Loci:
 3q26 gain (red)
 5p15 gain (green)
 Cen7 (aqua)
 20q13 gain (gold)

Community Hospitals
Regional Cancer Centers
Oncologists and Pathologists
• Continue to growing sales force that calls on hospitals
and regional laboratories
• Plan development of national footprint through
Expand Dx™
Biotechnology Companies
Pharmaceutical Companies
• Leverage clinical infrastructure and proprietary product
portfolio for testing services that support clinical trials
• Expand sales emphasis of Select One®
Emerging Markets
• Enhance distributor base in select emerging economies
• Partner with leading local cancer care providers and
hospitals to provide probes, arrays and clinical services
• Collaborate to create and validate microarrays and
other proprietary products
• Accelerate launch of large scale studies
Universities and Research Centers
Large, Targeted Market Opportunities
Commercialization StrategyTarget Markets

• Delivers better outcomes to community
hospitals and laboratories
• Enables community hospitals to bring
“state-of-the-art” genomic testing to
patients
• Brings personalized medicine to the
community hospital vs. just at
academic and teaching hospitals
• Allows community hospitals to keep
patients and treat them locally
• Improving care and quality is critical to
maintaining reimbursement for
community hospitals
$600,000 - $800,000 USD in Testing
Opportunity on Average per Hospital
Expanding & Developing Cancer Care is a
Top Priority for Hospital CEOs & CFOs
4,000 to 5,000 Community Hospitals
& Laboratories in the U.S.
85% Of All U.S. Cancer Patients are Initially
Diagnosed in Community Hospitals &
Laboratories
Unique Service Offering Developed to Enable Community
Hospitals to Improve Cancer Outcomes & Treat Patients Locally

Strong Growth in Clinical Trial Contracts with Oncology
Programs at Leading Biotech & Pharma Companies
Approximate expected future revenues under signed contracts with biotechnology and pharma
customers for testing and services to support currently planned clinical trials.
CGI IS ACTIVELY PROVIDING TESTING, GENOMIC SERVICES, AND BIOMARKER
SUPPORT FOR
December 2013December 2012 December 2014 March 2015

Strong History of Growth
Revenue Trends (2014 Year End and Q1 2015)
Year End Total Revenue ($Mn) Q1 Total Revenue ($Mn)
 $10.2 Mn revenue, up 54% Yr./Yr.
 Biopharma revenue grew 112% Yr./Yr.
$3.0
$4.3
$6.6
10.2
2011 2012 2013 2014
$
36%
CAGR
201420132011 2012
 $4.4 Mn revenue, up 206% Qtr./Qtr.
 Biopharma revenue grew 578% Qtr./Qtr.
$0.8
$1.2
$1.4
$4.4
Q1, 2012 Q1, 2013 Q1, 2014 Q1, 2015Q1, 2015Q1, 2014Q1, 2013Q1, 2012
53%
CAGR

Summary Statement of Operations
Income Statement Item
($ in Thousands)
Q1 2013 Q1 2014 Q1 2015
Revenue $1,219 $1,430 $4,370
Gross Profit 149 140 1,229
Gross Margin (%) 12% 10% 28%
Research & Development (R&D) 491 597 1,278
Sales & Marketing (S&M) 397 749 1,116
General & Administrative (G&A) 1,571 2,731 2,987
Operating Profit (Loss) (2,309) (3,936) (4,152)
Net Income (Loss) 2,360 (2,486) (4,278)
Balance Sheet Information Actual 03/31/15
All Cash* $28,612
Stockholders’ Equity 30,972
$ in thousands * All cash includes $6,300 of restricted cash.
$6,000 of that is now unrestricted as of May 7, 2015.
(Cancer Genetics, Inc. 2014 YE 10Q, page 77)

Revenues by Category
76%
20%
4%
Q1
2015
BIOPHARMA SERVICES
CLINICAL SERVICES
DISCOVERY SERVICES
$10.2 Mn $4.4 Mn
 Launched new NGS panels, including
Focus::Myeloid™
 Repositioning of Go-To Market Strategy to
concentration on clinical sales
 New research studies with leading cancer
centers and academic institutions
 Focus::Hotspot™ NGS panel for solid tumors
adopted in multiple research programs in India
 Selected to power molecular and biomarker
testing for six clinical trials
 Focus::CLL™ chosen for global clinical trial
by leading biotechnology company
$3.3 M
$873 K
$166 K

Consistent Achievement of Milestones Expected
in Coming Quarters
 Increasing covered lives market access through additional payers & health care organizations
 Additional international agreements for FHACT® distribution and co-marketing partnerships in key geographies
 Launching multi-marker NGS panel for lymphoid malignancies
 Multiple Myeloma NGS panel launch, Oncospire  Second half of 2015
 Lymphoid, Myeloid and CLL Panels - Additional data and results to support clinical usage, patient value and payor
coverage
 FHACT® - Additional data from a study conducted in conjunction with NCI and more published papers focused on
FHACT®, including a health economic study
 Additional news on biopharma partners & relationships
 Major collaborations with US & Asia biopharma companies

Scientific Advisory Board
Andrea Califano, Ph.D.
Chairman of the Columbia Initiative for Systems Biology
Associate Director for Bioinformatics, Herbert Irving Comp. Cancer Ctr
Timothy A. Chan, M.D., Ph.D.
Principal Investigator, Human Oncology and Pathogenesis Program at
Memorial Sloan-Kettering Cancer Center
Riccardo Dalla-Favera, M.D.
Director, Institute for Cancer Genetics at Columbia University
Vundavalli V. Murty, Ph.D.
Director, Cancer Cytogenetic Laboratory and Molecular Pathology at
Columbia University
Hans-Guido Wendel, M.D.
Principal Investigator, Cancer Genetics Laboratory at Memorial Sloan-
Kettering Cancer Center
Howard McLeod, PharmD
Medical Director, DeBartolo Family Personalized Medicine Institute, Moffitt
Cancer Center
Panna Sharma President & CEO
• 15+ years as advisor to global life science & healthcare cos.
• General Manager of Oncospire Genomics, JV with Mayo Clinic
• Founded TSG Partners
• Chief Strategy Officer, iXL (IIXL)
Edward J. Sitar Chief Financial Officer & Treasurer
• 30+ yrs in finance & deal making in the healthcare industry
• Healthagen, ActiveHealth Management, Cadent Holding, MIM Corporation
(Bioscrip), Vital Signs, Zenith/Goldline Pharmaceutical, Coopers & Lybrand
Jane Houldsworth, Ph.D. Vice President of R&D
• 25+ years in translational oncology research
• Published 50+ articles, 4 patents
• NIH grantee
Rob Fannon Vice President of Operations
• 10+ years operations, client management, molecular test & panel
development, and biorepository management
• Roche Molecular Systems, BioServe Biotechnologies, Ltd., Stansberry &
Associates Investment Research
John Pappajohn [Chairman] | Edmund Cannon | Raju Chaganti, Ph.D. | Geoffrey Harris
Howard McCleod, Pharm.D. | Franklyn Prendergast, M.D., Ph.D. | Panna Sharma | Michael J. Welsh M.D.
Board of Directors
Officers & Management Team
Experienced and Focused Management and Boards

• Strong and growing portfolio in molecular-focused patents for disease identification & stratification
• IP-based on unique algorithms across a broad group of chromosomal regions
• Validation of specific clinical endpoints that are associated with particular disease
outcomes or decisions
• Filing and maintenance of trademark portfolio
Tool for Diagnosis and Prognosis of Mature B-Cell Neoplasms
• US Issued Patent 8,580,713
• Europe 10803548.6
• India 6657/DELNP/2012
• Canada 2,785,656
Methods of Analyzing Chromosomal Translocations Using
Fluorescence In Situ Hybridization (FISH)
• Canada 2,447,320 – Foreign Counterpart Patent
Panel for the Detection & Differentiation of Renal Cortical Neoplasms
• Europe 08844570.5
Methods for Detecting Human Papilloma Virus-Associated Cancers
• PCT/US2011/050681
Methods and Tools for the Diagnosis of Female Gynecological
Cancers and Precancers
• US 61/581,350
IP Position and Detailed Global Strategy

Thank you Nasdaq
(CGIX)
CGI Headquarters
Meadows Office Complex
201 Route 17 North, 2nd Fl.
Rutherford, NJ 07070
Phone: +1 201-528-9200
Fax: +1 201-528-9235
RUTHERFORD, NJ
Research Triangle Park
133 Southcenter Court, S.400
Morrisville, NC 27569
Phone: +1 919-465-0100
Fax: +1 919-465-0554
RALEIGH, NC
#3-1-135 / 1A CNR Complex
Mallapur Main Road, R.R. Dst.
Hyderabad – 500 076, Telangana
Toll-free: +91 040-2717-8178
Fax: +91 040-2717-8176
HYDERABAD, INDIA
781 Cai Lun Road, Room 803
Shanghai 201203
P.R. China
Toll-free: +91 040-2717-8178
Fax: +91 040-2717-8176
SHANGHAI, CHINA
For further information, please contact us at ir@cgix.com

Cgix 201506

Recommandé

Recommandé

Contenu connexe

Tendances

Tendances (20)

Similaire à Cgix 201506

Similaire à Cgix 201506 (20)

Plus de RedChip Companies, Inc.

Plus de RedChip Companies, Inc. (20)

Dernier

Dernier (20)

Cgix 201506